 Connection
David Badesch to Familial Primary Pulmonary Hypertension
This is a "connection" page, showing publications David Badesch has written about Familial Primary Pulmonary Hypertension.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.007 |
|
|
|
-
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023 01; 61(1).
Score: 0.199
-
Klinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB. Response. Chest. 2019 07; 156(1):187-188.
Score: 0.156
-
Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemari? JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015 Jul; 46(1):152-64.
Score: 0.116
-
Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014 Aug; 146(2):449-475.
Score: 0.111
-
Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Waxman AB, Gr?nig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Lin J, Johnson-Levonas AO, de Oliveira Pena J, Humbert M, Hoeper MM. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. 2023 09; 62(3).
Score: 0.052
-
McCormick A, Krishnan A, Badesch D, Benza RL, Bull TM, De Marco T, Feldman J, Hemnes AR, Hirsch R, Horn E, Kennedy J, Mathai SC, McConnell W, Pugliese SC, Sager JS, Shlobin OA, Simon MA, Lammi MR. Pulmonary artery compliance in different forms of pulmonary hypertension. Heart. 2023 06 26; 109(14):1098-1105.
Score: 0.051
-
Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022 05 03; 11(9):e024969.
Score: 0.047
-
Kolaitis NA, Zamanian RT, de Jesus Perez VA, Badesch DB, Benza RL, Burger CD, Chakinala MM, Elwing JM, Feldman J, Lammi MR, Mathai SC, McConnell JW, Presberg KW, Robinson JC, Sager J, Shlobin OA, Simon MA, Kawut SM, Glidden DV, Singer JP, De Marco T. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc. 2021 04; 18(4):613-622.
Score: 0.044
-
Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 02; 57(2).
Score: 0.044
-
Frantz RP, Zhao C, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Mink DR, Selej M, Benza RL. Response. Chest. 2018 11; 154(5):1262-1264.
Score: 0.037
-
Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013 Nov; 144(5):1521-1529.
Score: 0.026
-
Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1.
Score: 0.026
-
Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Gali? N. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012 Dec; 142(6):1383-1390.
Score: 0.025
-
Rubin LJ, Simonneau G, Badesch D, Gali? N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 01; 21(125):234-8.
Score: 0.024
-
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug; 142(2):448-456.
Score: 0.024
-
Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011 Sep 27; 124(13):1452-60.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|